White House drops Trump’s FDA pick ahead of confirmation vote

CNN
Original Story by CNN
November 18, 2026
White House drops Trump’s FDA pick ahead of confirmation vote

The White House has withdrawn the nomination of a deputy White House policy official to lead the FDA after confirmation hearings raised concerns about vaccines and the potential for political interference in agency decision-making, which could erode public trust. The move highlights the administration’s difficulty in appointing an FDA commissioner who can navigate public health policy while preserving scientific independence. The withdrawal follows scrutiny over vaccine stances and the agency’s role in safety decisions, against a backdrop of opposition from lawmakers and public health advocates. The episode signals challenges ahead for maintaining credibility and autonomy at the FDA, with no immediate replacement announced. Momentum suggests a pause in leadership transition at the agency as the administration reassesses candidate suitability and Senate support.

Dive Deeper:

  • The nomination was for the position to succeed a previous FDA leader who resigned in May, with the candidate serving as deputy director of the White House Domestic Policy Council.

  • During confirmation hearings, the nominee faced questions about vaccines, including the MMR vaccine, with the candidate affirming its safety and efficacy in response to Senate queries.

  • Critics, including some senators and public health advocates, raised concerns about potential political interference in the FDA’s decision-making processes.

  • The episode underscores broader challenges the administration faces in appointing an FDA commissioner who can balance public health policy, scientific integrity, and political considerations.

  • The withdrawal ends the formal nomination process for this candidate, creating uncertainty about future leadership and the approach the administration will take toward FDA independence.

  • No immediate replacement has been announced, indicating a period of assessment and strategic consideration regarding the agency’s leadership and credibility.

Latest News

Related Stories